Cost-effectiveness Analysis Comparing Vonoprazanbased Triple Therapy with Proton Pump Inhibitorbased Therapy in the Treatment of Helicobacter pylori Infection in Thailand
Objective: Helicobacter pylori (H. pylori) infection is one of the leading causes of gastrointestinal diseases such as dyspepsia, peptic ulcers. Thailand has a 45.9% prevalence of the infection and an increasing rate of resistance to clarithromycin, leading to standard treatments being less success...
Guardado en:
Autores principales: | Jadesada Lertsirimunkong, Wiwat Thavornwattanayong, Yosita Napuk, Watcharapong Ajcharoen, Vipavee Chaisitsanguan, Supasuta Wachiranukornkul |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Mahidol University
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b7d017151aa64bde9b4957197d1762bd |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pilot study: Comparing efficacy of 14-day triple therapy Clarithromycin versus levofloxacin on eradication of Helicobacter Pylori infection in Syrian population single-center experience
por: Khaled Mohammad Cheha, et al.
Publicado: (2018) -
Tratamiento de la infección por Helicobacter pylori en pacientes con úlcera duodenal: Estudio de costo-beneficio
por: Rollán R,Antonio, et al.
Publicado: (2000) -
Effect of proton pump inhibitor use on Helicobacter pylori positivity and atrial fibrillation
por: Atay K, et al.
Publicado: (2015) -
Effects of Proton Pump Inhibitor Therapy, H. pylori Infection and Gastric Preneoplastic Pathology on Fasting Serum Gastrin Concentrations
por: Reuben Veysey-Smith, et al.
Publicado: (2021) -
Genotipificación de aislados clínicos de Helicobacter pylori en base a genes asociados a virulencia cagA, vacA y babA2: Primer aislamiento de una cepa babA2 positiva en pacientes chilenos
por: García C,Apolinaria, et al.
Publicado: (2006)